Cambridge Heart, Inc. is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company's products incorporate the Company's technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient's heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses. The Company's products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States.
|Headquarters||100 AMES POND ROAD|
TEWKSBURY, MA, United States 1876
|President, Treasurer, Secretary, Director||Craig Jalbert|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P Capital IQ, INK and Argus.
|Shares Out.||100.1M||Book Value||$-0.13|
|Cambridge Heart Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.